Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)

New Plu­vic­to da­ta point to a po­ten­tial wider in­di­ca­tion, but No­var­tis leaves reg­u­la­to­ry time­line up in the air: #ES­MO23

MADRID — No­var­tis’ ra­dio­phar­ma­ceu­ti­cal drug Plu­vic­to staved off prostate can­cer pro­gres­sion for a me­di­an of six months longer than hor­mone ther­a­py in a piv­otal study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.